JPWO2020116498A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020116498A5 JPWO2020116498A5 JP2020559959A JP2020559959A JPWO2020116498A5 JP WO2020116498 A5 JPWO2020116498 A5 JP WO2020116498A5 JP 2020559959 A JP2020559959 A JP 2020559959A JP 2020559959 A JP2020559959 A JP 2020559959A JP WO2020116498 A5 JPWO2020116498 A5 JP WO2020116498A5
- Authority
- JP
- Japan
- Prior art keywords
- cxcr3 ligand
- cxcr3
- sequence
- amino acid
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 59
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 59
- 239000003446 ligand Substances 0.000 claims 52
- 150000001413 amino acids Chemical class 0.000 claims 20
- 238000000034 method Methods 0.000 claims 14
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 6
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 6
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 4
- 102000046438 human CXCL10 Human genes 0.000 claims 4
- 238000013508 migration Methods 0.000 claims 4
- 230000005012 migration Effects 0.000 claims 4
- 102000055715 human CXCL11 Human genes 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108010023201 ITAC peptide Proteins 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018227353 | 2018-12-04 | ||
| JP2018227353 | 2018-12-04 | ||
| PCT/JP2019/047382 WO2020116498A1 (ja) | 2018-12-04 | 2019-12-04 | Cxcr3リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020116498A1 JPWO2020116498A1 (ja) | 2021-10-14 |
| JPWO2020116498A5 true JPWO2020116498A5 (cg-RX-API-DMAC7.html) | 2022-12-07 |
| JP7438975B2 JP7438975B2 (ja) | 2024-02-27 |
Family
ID=70974705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559959A Active JP7438975B2 (ja) | 2018-12-04 | 2019-12-04 | Cxcr3リガンド |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US12624077B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3892330A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7438975B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020116498A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3892330A4 (en) | 2018-12-04 | 2022-10-26 | Chugai Seiyaku Kabushiki Kaisha | CXCR3 LIGAND |
| CA3194929A1 (en) * | 2020-06-21 | 2021-12-30 | Technion Research & Development Foundation Limited | Modified cxcl10 for immunotherapy of cancer diseases |
| US20230242606A1 (en) * | 2020-06-21 | 2023-08-03 | Technion Research & Development Foundation Limited | Cxcl9 and variants thereof for immunotherapy of cancer diseases |
| WO2023120643A1 (ja) | 2021-12-23 | 2023-06-29 | 中外製薬株式会社 | Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。 |
| CN121338000B (zh) * | 2025-11-13 | 2026-08-04 | 中山大学 | Rab30-dt抑制剂在制备预防和治疗肿瘤的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999028474A2 (en) | 1997-12-01 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services | Chemokine variants and methods of use |
| AU2903999A (en) * | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| US7091310B2 (en) * | 2002-09-13 | 2006-08-15 | Chemokine Therapeutics Corporation | Chemokine analogs for the treatment of human disease |
| WO2003082335A1 (fr) * | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe |
| CA2525647A1 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US20090131312A1 (en) | 2005-05-18 | 2009-05-21 | Lawrence Blatt | Non-natural chemokine receptor ligands and methods of use thereof |
| US7696309B2 (en) | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| WO2012172336A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
| EP3096777B1 (en) | 2014-01-21 | 2021-01-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Goblet cell replacement therapy |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| EP3892330A4 (en) | 2018-12-04 | 2022-10-26 | Chugai Seiyaku Kabushiki Kaisha | CXCR3 LIGAND |
| WO2021038033A1 (en) | 2019-08-29 | 2021-03-04 | Antagonis Biotherapeutics Gmbh | T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity |
| WO2023120643A1 (ja) | 2021-12-23 | 2023-06-29 | 中外製薬株式会社 | Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。 |
-
2019
- 2019-12-04 EP EP19893138.8A patent/EP3892330A4/en active Pending
- 2019-12-04 US US17/299,629 patent/US12624077B2/en active Active
- 2019-12-04 JP JP2020559959A patent/JP7438975B2/ja active Active
- 2019-12-04 WO PCT/JP2019/047382 patent/WO2020116498A1/ja not_active Ceased
-
2026
- 2026-04-08 US US19/641,701 patent/US20260217779A1/en active Pending